Sugi Predict

Sugi Predict / Compounds / SCHEMBL180293

SCHEMBL180293

SCHEMBL180293

Cc1ccc(S(=O)(=O)OCC2CCN(C(=O)O)CC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ F2 P00734 3/20 0.45
▸ CYP2D6 P10635 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ KMT2A Q03164 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ STAT3 P40763 1/20 0.42
▸ GRIN2B Q13224 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ GAA P10253 1/20 0.41
▸ PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13740063 0.92 ALDH1A1 (0.45) ALDH1A1KDM4EF2CYP2D6LMNA
SCHEMBL13738496 0.92 ALDH1A1 (0.45) ALDH1A1KDM4EF2CYP2D6LMNA
SCHEMBL7000711 0.92 ALDH1A1 (0.45) ALDH1A1KDM4EF2CYP2D6LMNA
SCHEMBL1502234 0.89 ALDH1A1 (0.45) ALDH1A1KDM4EF2CYP2D6LMNA
SCHEMBL3143764 0.89 ALDH1A1 (0.40) ALDH1A1KDM4EF2LMNAPOLB
SCHEMBL20323490 0.87 EPHX2 (0.48) ALDH1A1KDM4EF2LMNAPOLB
SCHEMBL20323431 0.87 NPC1 (0.50) ALDH1A1KDM4EF2CYP2D6LMNA
SCHEMBL2389377 0.87 ALDH1A1 (0.45) ALDH1A1KDM4ECYP2D6LMNAPOLB
SCHEMBL1502067 0.87 ALDH1A1 (0.48) ALDH1A1KDM4EF2CYP2D6LMNA
SCHEMBL20300372 0.87 NPC1 (0.56) ALDH1A1KDM4ELMNAPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118201909-A Quinazoline derivative compound and use thereof 株式会社沃若诺伊 2024-06-14 — — CN disclosed
WO-2024072178-A1 COMPOUND FOR TARGETED PROTEIN DEGRADATION, AND USE THEREOF (주)사이러스테라퓨틱스 2024-04-04 — — WO disclosed
EP-4234017-A2 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS USEFUL FOR THE TREATMENT OF CARDIAC DISORDERS SUCH AS DILATED CARDIOMYOPATHY (DCM) MyoKardia, Inc. (US) 2023-08-30 — — EP disclosed
EP-3247707-B1 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS USEFUL FOR THE TREATMENT OF CARDIAC DISORDERS SUCH AS DILATED CARDIOMYOPATHY (DCM) MYOKARDIA INC (US) 2023-05-31 — — EP disclosed
WO-2023075529-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF 보로노이바이오 주식회사 2023-05-04 — — WO disclosed
EP-3256464-B1 COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY CHIESI FARM SPA (IT) 2022-05-11 — — EP disclosed
US-20220117955-A1 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS MyoKardia, Inc. 2022-04-21 — — US disclosed
US-11123337-B2 4-methylsulfonyl-substituted piperidine urea compounds MyoKardia, Inc. (US) 2021-09-21 — — US disclosed
EP-3829561-A1 SUBSTITUTED-3H-IMIDAZO[4,5-C]PYRIDINE AND 1H PYRROLO[2,3-C]PYRIDINE SERIES OF NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR INTERFERON GENES (STING) MODULATORS AS CANCER IMMUNOTHERAPEUTICS Stingray Therapeutics, Inc. (US) 2021-06-09 — — EP disclosed
US-20200345716-A1 4-Methylsulfonyl-Substituted Piperidine Urea Compounds MyoKardia, Inc. 2020-11-05 — — US disclosed
CN-1289469-C Alpha-(n-sulphonamido)acetamide derivatives as beta-amyloid inhibitors BRISTOL MYERS SQUIBB CO (US) 2006-12-13 — — CN disclosed
WO-2006110917-A2 SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2006-10-19 — — WO disclosed
EP-1575946-A1 QUINAZOLINE COMPOUNDS AstraZeneca AB (SE) 2005-09-21 — — EP disclosed
CN-1656081-A 4-Anilinoquinazoline derivatives as antiproliferative agents ASTRAZENECA AB (SE) 2005-08-17 — — CN disclosed
CN-1617852-A Alpha- (N-sulfonamido) acetamide derivatives as beta-amyloid inhibitors BRISTOL MYERS SQUIBB CO (US) 2005-05-18 — — CN disclosed
WO-2004058752-A1 QUINAZOLINE COMPOUNDS ASTRAZENECA AB (SE) 2004-07-15 — — WO disclosed
US-20030212094-A1 Novel cyclic amide derivatives MITSUBISHI PHARMA CORPORATION (JP) 2003-11-13 — — US disclosed
EP-1260512-A1 NOVEL CYCLIC AMIDE DERIVATIVES Mitsubishi Pharma Corporation (JP) 2002-11-27 — — EP disclosed
EP-1140915-A1 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES FOR TREATING GASTROINTESTINAL DISORDERS JANSSEN PHARMACEUTICA N.V. (BE) 2001-10-10 — — EP disclosed
WO-2000037461-A1 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES FOR TREATING GASTROINTESTINAL DISORDERS JANSSEN PHARMACEUTICA N.V. (BE) 2000-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220117955-A1 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS TNNI3, UMPS, TNNT2 ALDH1A1 3067/4885KDM4E 45/4885F2 4766/4885
US-20030212094-A1 Novel cyclic amide derivatives SIGMAR1, OPRM1, OPRD1 ALDH1A1 690/4885KDM4E 2058/4885F2 4078/4885
US-20200345716-A1 4-Methylsulfonyl-Substituted Piperidine Urea Compounds TNNI3, UMPS, TNNT2 ALDH1A1 3067/4885KDM4E 45/4885F2 4766/4885
US-11123337-B2 4-methylsulfonyl-substituted piperidine urea compounds TNNI3, UMPS, TNNT2 ALDH1A1 3067/4885KDM4E 45/4885F2 4766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.